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This review discusses the pathophysiology, evaluation, and treatment of neuromuscular,
musculoskeletal, and functional disorders that can result as late effects of radiation treat-
ment.
Although radiation therapy is often an effective method of killing cancer cells, it can also
damage nearby blood vessels that nourish the skin, ligaments, tendons, muscles, nerves,
bones and lungs. This can result in a progressive condition called radiation ﬁbrosis syn-
drome (RFS). It is generally a late complication of radiotherapy which may manifest clinically
years after treatment. Radiation-induced damage can include “myelo-radiculo-plexo-neuro-
myopathy,” causing muscle weakness and dysfunction and contributing to neuromuscular
injury.
RFS  is a serious and lifelong disorder which, nevertheless, may often be decrementedwhen identiﬁed and rehabilitated early enough. This medical treatment should be a complex
procedure consisting of education, physical therapy, occupational therapy, orthotics as well
as  medications.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
trointestinal and genitourinary tracts, bone, or other organs,.  Background
he status of cancer patient results not only from the direct
nd indirect effects of the disease but also from treatments
uch as surgery, radiotherapy, and chemotherapy.1,2 These
reatments may result in musculoskeletal and neuromus-
ular complications as well as dysfunction of any visceral
rgan, including the heart, lungs, gastrointestinal tract, and
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507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
ttp://dx.doi.org/10.1016/j.rpor.2013.07.007genitourinary tract.1,3 Radiation-induced toxicity may be a
result of acute radiation or a long-term disability following
cancer treatment during radiation ﬁbrosis syndrome (RFS).4,5
RFS can affect any tissue type, including the skin, ligament,
tendon, muscles, viscera, nerve, as well as lungs, the gas-d Cancer Center, 15 Garbary Street, 61-866 Poznan, Poland.
depending upon the treatment site.6–8 It is generally a late
complication of radiotherapy which may not manifest clini-
cally for years after treatment.9 RFS may cause both functional
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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and cosmetic impairment, which can lead to death or a sig-
niﬁcant deterioration in the quality of life (QoL).
2.  Aim
The objective of the study was to review articles about
physiopathology, and clinical evaluation of opportunities for
rehabilitation in RFS patients.
3.  The  physiopathology  of  RFS
RFS is similar to inﬂammation, wound healing, and ﬁbrosis
of any origin. Typical histologic features include the pres-
ence of inﬂammatory inﬁltrates, particularly macrophages in
the earlier stages of ﬁbrosis, differentiation of ﬁbroblasts into
postmitotic ﬁbrocytes, and changes in the vascular connective
tissue with excessive production and deposition of extra-
cellular matrix proteins and collagen. Among the secreted
factors driving ﬁbrosis, is the transforming growth factor beta
1 (TGF-1) produced by a wide range of inﬂammatory, mes-
enchymal and epithelial cells which converts ﬁbroblasts and
other cell types into matrix-producing myoﬁbroblasts. After
myoﬁbroblast activation, collagen production can be perpet-
uated independently of TGF-1 by autocrine induction of a
cytokine called connective tissue growth factor.10 Although
TGF-1 is certainly a key cytokine, the ﬁbrotic process cannot
be explained by a single factor. TGF-1 regulates epidermal
growth factor (EGF), ﬁbroblast growth factor (FGF), tumor
necrosis factor (TNF ), and IL-1 by stimulating or inhibiting
their production in various cell types, including ﬁbroblasts,
endothelial cells, and smooth muscle cells.11 It involves a
complex network of interacting cytokines and growth fac-
tors, which include radiation ﬁbrosis IL-1, insulin-like growth
factor-1 (IGF-1), and TNF . Three histopathological phases
of radiation ﬁbrosis have been described,10 including: (1) a
preﬁbrotic phase characterized by chronic inﬂammation in
which endothelial cells are thought to play an important role;
(2) an organized ﬁbrosis phase with patchy areas of active
ﬁbrosis containing a high density of myoﬁbroblasts in an unor-
ganized matrix adjacent to poorly cellularized ﬁbrotic areas
of senescent ﬁbrocytes in a dense sclerotic matrix; and (3)
a late ﬁbroatrophic phase, characterized by retractile ﬁbrosis
and gradual loss of parenchymal cells. The mechanisms link-
ing radiation to chronic vascular dysfunction and subsequent
tissue sclerosis, ﬁbrosis, and atrophy are complex and not
completely understood. In one theory, Hauer-Jensen et al.12
postulates that the predominant mechanism by which radia-
tion causes tissue injury in tumors and normal tissues is the
induction of apoptosis via free radical-mediated DNA dam-
age. In normal tissues, radiation toxicity occurs in response
to a sequence of overlapping events that are attributable to
direct radiation-induced changes in cell function as well as
indirect responses to tissue injury, causing activation of the
coagulation system, inﬂammation, epithelial regeneration,
and tissue remodeling, which is precipitated by molecular
signals including cytokines, chemokines, and growth factors.
Injury to the vascular endothelium probably plays a role inadiotherapy 1 9 ( 2 0 1 4 ) 1–6
the response of most normal tissues to ionizing radiation. The
abnormal accumulation of ﬁbrin in the intravascular, perivas-
cular, and extravascular compartments may be responsible for
the progressive tissue ﬁbrosis and sclerosis that characterizes
RFS.13
The possible factors that may determine a patient’s risk
of developing clinical manifestations of RFS include age,
medical and degenerative disorders, cancer status, partic-
ularly degenerative spine disease, exposure to neurotoxic,
cardiotoxic, and other chemotherapy types.5,14 Another factor
in the development of radiogenic lung ﬁbrosis is concomitant
tamoxifen therapy as well as location, size of ﬁeld, and type
of radiation.5,15
4.  Radiation  and  RFS
Factors associated with a greater risk of RFS include com-
bining other treatment modalities with radiotherapy (i.e.
surgery and/or chemotherapy, endocrine therapy), large-
volume radiotherapy plans, high total radiotherapy dose,
unusually high dose per fraction regimens, coincident infec-
tion or operative complications (e.g. wound drainage, and
extensive hematoma), and inhomogeneity of dose delivery.
The effects of radiation are cumulative, and patients radiated
more  than once at the same location for recurrent disease
can be expected to develop worse radiation ﬁbrosis. Patients
given higher than normal doses of radiation are more  likely
to develop complications. Although subcutaneous radiation
ﬁbrosis is probably the most common manifestation of radia-
tion injury, the exact depth in the skin most responsible for
the ﬁbrotic process is unclear. Bentzen et al.16 proposed a
range of 3.3–5.5 mm as acceptable reference point for subcu-
taneous ﬁbrosis in the breast, with the best estimate at the
depth of 4.1 mm.  They also suggested that the best estimate
for the alpha/beta ratio is 1.8 for the ﬁbrosis endpoint. The
reason why this may be important is that contemporary 3-
dimensional radiotherapy planning systems do not model this
dose satisfactorily because it exists in the steep dose gradient
build up zone. For subcutaneous ﬁbrosis in the neck tissues,
Hirota et al.16 speciﬁed the skin-absorbed dose at the depth
of 4.1 mm (d4.1-mm depth) in the ﬁeld center according to the
recommendations of Bentzen et al.16 They found that the d4.1-
mm depth was affected by the number of ﬁelds used and the
application of certain techniques such as electron boosts com-
pared with photons. They showed a time dependence in the
onset of radiation ﬁbrosis and that patients undergoing prior
surgery (neck dissection) have a higher incidence of subcuta-
neous ﬁbrosis than those without surgery, conﬁrming that the
effects of multimodality treatment in addition to the accuracy
of dose calculation must be taken into account in estimat-
ing late tissue effects. The inﬂuence of other factors including
total dose as the biologically equivalent dose (BED) at d4.1-mm
depth, fractionation, and systemic agents are also evident.17
Dose sculpting techniques include intensity-modulated radio-
therapy (IMRT) and image-guided radiotherapy18 which allows
a non uniform coverage of the radiation ﬁeld to minimize
exposure to normal tissues while maximizing the dose to the
tumor by shaping the beam to closely approximate its shape in
3 dimensions. The radiation can be controlled to such a degree
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5.5.  Lungreports of practical oncology a
hat radiosensitive structures such as the spinal cord can be
pared, even if they are only a few millimeters away from the
umor.12 This technique provides for very high doses of radia-
ion to be administered to the tumor volume in fewer fractions,
ften a single fraction, and has dramatically changed our
reatment strategies for many  tumors. Some ﬁelds of radiation
re quite extensive, as in the mantle ﬁeld radiation port used
o treat Hodgkin lymphoma which involves all lymph nodes
n the mediastinum, neck (cervical supraclavicular, infraclav-
cular), or axilla. Patients radiated for head and neck cancer
HNC) are likely to develop RFS due to high dose of radiation.
n the other hand, the radiation ﬁeld can be focal, as when
reating isolated vertebral metastasis, extremity sarcoma.19,20
.  The  complication  of  RFS
he neuromuscular and musculoskeletal complications of
FS stem from both direct and indirect effects of progres-
ive ﬁbrosis on the nerves, muscle, tendons, ligaments, skin,
ones, and lymphatic system. Any level of the nervous sys-
em can be affected in RFS. The clinical effects of RFS-induced
erve dysfunction are pain, sensory loss, and weakness. The
equel damage of autonomic nerves may include orthostatic
ypotension, bowel and bladder dysfunction, or sexuality
ysfunction.21 Neuropathic pain is an extremely common
omponent of RFS. The mechanisms contributing to the gen-
ration of neuropathic pain are complex and involve processes
n the central and peripheral nervous system.22 A factor prob-
bly common to the pathogenesis of neuropathic pain in RFS
s the generation of ectopic activity in a radiation damaged
omponent of the sensory nervous system. Radiation-induced
ctopic activity can develop in any affected neural structure,
ncluding the thalamus, ascending spinothalamic tracts of
he spinal cord, nerve roots, plexus, and peripheral nerves.
he etiology of the ectopic signal can be compressive and/or
schemic with subsequent demyelisation and or axonal loss.
adiation damage to the funiculi of the cervical spinal cord, for
nstance, can cause pain perceived in any body part caudal to
he lesion. This may result in pain in the thorax, abdomen,
r lower extremities and mimic  radiculopathy, plexopathy,
olyneuropathy, or mononeuropathy, with more  than one
ody area, unilaterally or bilaterally, being affected. Peripheral
ervous system dysfunction can result from ischemia due to
tenosis of the vaso vasorum, from external ﬁbrosis of soft
issues.23,24 Neuropathic pain is often accompanied by loss
r perturbation of sensation. Sensory loss can exist without
ain. The primary faculties affected include light touch, pain,
emperature, vibration, and position sensation. A deﬁcit in
ny of these can potentially render the survivor susceptible
o other injuries. Similarly, sensory loss can affect gait and
erformance of activities of daily living. Damage to the nerve
oots cause weakness in a myotomal pattern, and ﬁbrosis in
uscle ﬁbers within the radiation ﬁeld can cause focal myopa-
hy. The damage to the cervical paraspinal muscles combined
ith the damage to neural structures causes the progressive
eck weakness and head drop often observed in HNC sur-
ivors. Radiation-induced plexopathy can affect the cervical,
rachial, and lumbosacral plexus depending on the radiation
eld and results in functional disability. Mononeuropathiesdiotherapy 1 9 ( 2 0 1 4 ) 1–6 3
caused by radiation should be obvious when a major structure
such as the sciatic nerve is involved in the radiation ﬁeld.25
Dysfunction of the dorsal scapular nerve to the rhomboids or
the suprascapular nerve to the supraspinatus and infraspina-
tus is important to the pathogenesis of shoulder dysfunction
in many  cancer survivors.
5.1.  Muscles
Myopathic muscles are prone to painful spasms mediated
by several pathologic mechanisms, including the myopathy
itself, relative weakness and fatigability of muscles. This pro-
cess may contribute to disorders such as radiation-induced
cervical dystonia in HNC patients, in whom the sternoclei-
domastoid and scalene muscles are affected by radiation
resulting in severe spasms and, ultimately, contracture of
the neck.26 The continuous muscle contraction also results
in constriction of local blood supply with subsequent tissue
hypoxia. Local hypoxia and acidiﬁcation result in the release of
inﬂammatory mediators, cytokines, and neuropeptides with
sensitization of nociceptive nerve ﬁbers. The sensitization of
these local pain neurons results in the generalization of mus-
cle pain.27
5.2.  Tendons  and  ligaments
The effect of radiation on tendons and ligaments is one of
progressive ﬁbrosis with consequent loss of elasticity, short-
ening, and contracture. They can often cause the loss of range
of motion in joints and their function. The effects of radiation
do not always have to be direct. For instance, radiation to an
upper leg can result in marked ankle contracture via effects
on the muscles, tendons, and neurovascular innervation of
the distal leg.
5.3.  Bone
Radiation renders bone brittle and proness to injury, including
osteoradionecrosis of the mandible, pelvic insufﬁciency frac-
ture, hip fracture, long bone fracture, rib fracture.28 Osteopenia
and osteoporosis are diseases that are common and potential
late-term complications of radiation, leaving patients more
susceptible to osteoporotic fractures in later life.29
5.4.  Skin
Radiation-induced dermatitis is a major acute complication of
radiation therapy and usually improves in time.30 Chronic skin
changes include progressive ﬁbrosis, sclerosis, and in dura-
tion with tenacious and intractable adherence to underlying
tissues.The early histopathologic ﬁndings are described as diffuse
alveolar damage. This includes edema of the alveolar walls,
intra-alveolar hemorrhage, vessel thrombosis and inﬁltration
with inﬂammatory cells.31
and r4  reports of practical oncology 
6.  Clinical  evaluation  in  RFS
The diagnosis of RFS is not always straight forward. Symp-
toms can be referable with a history of radiation therapy. It
should include all preexisting medical conditions, particu-
larly musculoskeletal, and neuromuscular conditions such as
tendonitis, cervical radiculopathy, and neuropathy. The symp-
toms of RFS can develop during radiation or years later. The
details of the patient’s pain, spasm, tightness and the language
they use to describe their symptoms are important. Signs may
be nonspeciﬁc, but often described as “pulling”, “cramping”.
Neuropathy terms such as “stabbing”, “searing”, and “burn-
ing” can be used to describe the pain associated with nerve
injury. Physical examination is of paramount importance in
understanding, and treating the clinical manifestation of RFS.
Imaging is often useful in the evaluation of RFS. Magnetic res-
onance imaging (MRI) is the test of choice for evaluating the
spine, soft tissue, joints. Computer tomogram (CT) in contrast
is usually used to image  the viscera of the chest, abdomen,
and pelvis. Electrodiagnostic (electroneurography – ENG, elec-
tromyography – EMG) is useful to identify, localize, conﬁrm,
and differentiate radiculopathy, plexopathy, neuropathy, or
myopathy in patients with RFS.1
7.  Rehabilitation
Rehabilitation has enjoyed tremendous success in reliev-
ing pain and improving the function and QoL of cancer
survivors.3,32 Rehabilitation using extensive training in neu-
romuscular and musculoskeletal medicine as well as in the
principles of functional restoration is uniquely positioned to
help direct efforts to improve QoL for cancer survivors with
RFS. The main goal of the maintenance of the rehabilitation in
chronic conditions is improvement of the affected body func-
tion and an increase in daily activities. This treatment has to
be a complex procedure consisting of education, physical ther-
apy, occupational therapy, orthotics as well as medications.1
7.1.  Education
Education is of paramount importance to cancer survivors
with RFS. Patients are, in general, extremely grateful when
they have a practitioner who will listen to them and try to
understand their complaints. They become hopeful when the
basic physiopathology and interrelationship of their disorders
are understood and explained to them.33
7.2.  Physical  therapy
The principles of physical therapy (PT) in cancer, the use of
therapeutic modalities and therapeutic exercise have been
discussed extensively.3,34–36 Physical activity during radiother-
apy has a positive effect on most parameters such as QoL,
fatigue, and ﬁtness.34–39 In patients with RFS, exercise should
be done to extend the range of motion in joints, and increase
muscle strength. In the case of loss (atrophy) of muscle, syner-
gistic muscles exercises can be introduced to compensate this.adiotherapy 1 9 ( 2 0 1 4 ) 1–6
PT, which should be postural retraining through core strength-
ening, ﬂexibility and conditioning of the muscles. Although
these muscles are impaired, they often respond well to reha-
bilitative efforts, and even small gains in muscle stamina
coupled with improved posture can translate into large func-
tional improvement for the patient. Correction of anatomic
posture alone will help decrease energy expenditure and pain
in most patients. Because the ﬁbrotic process that under-
lies RFS cannot be directly affected, insidious progression
of weakness and dysfunction is ultimately unavoidable. The
adherence to a life-long exercise program emphasizing home
maintenance exercises is of paramount importance to help
maximize and maintain function and QoL. After the systemic
therapy, patients require exercises of general ﬁtness type
in order to improve their physical efﬁciency.35,36 In patients
undergoing tumor treatment, the use of selected manipula-
tive techniques was reported that concerned patients with
breast cancer, HNC tumors and gastric carcinoma.40–42 RFS
may cause deformation and function disorders of the fascial
system that exerts a crucial inﬂuence on the mobility of joints,
abdominal and lumbar tissues, and consequently, of chest
walls.40,42 The fascial techniques consisting in expanding the
skin, subcutaneous connective tissue and deep fascia make it
possible to restore normal shifting of particular layers of soft
tissues.39,42 The myofascial relaxation was found to inﬂuence
the general homeostasis thanks to the loosening of tense soft
tissues enabling to reduce pain and improve circulation in the
region with RFS. In the process of patient recovery, visceral
manipulations were used to eliminate the dysfunction in the
region of internal organs and muscles through restoring nor-
mal  mobility, ﬂexibility and tension of tissues surrounding a
given organ and thereby causing better blood supply in the
organ.40,41
7.3.  Orthotic
The role of orthotic in the management of RFS follows the
same basic principles of orthotic use as in other neuromus-
cular and musculoskeletal disorders. The various designs of
cervical orthotics should be applied to control neck extensor
weakness. The biomechanical principles of their balance are
basic to the kinesthetic skeletal ﬁxation.43 When rehabilitative
efforts are inadequate to maintain adequate posture and pain
relief, a cervical orthotic (cervical collar) should be considered.
This is not intended for continuous use; it should be used as an
energy conservation device, instead. Patients with difﬁculty in
maintaining their head in an upright position or who  experi-
ence pain as the day progresses because of muscular overload
should wear the collar whenever possible. Activities to use the
collar include housework, eating, working with the computer,
watching television, and reading. Upper extremity orthotic is
used to improve function in patients with sever radiculopa-
thy or plexopathy.44 Lower extremity orthotics may be used
for patients with dorsiﬂexion weakness, including myelopa-
thy, plexopathy (lumbosacral trunk), radiculopathy. The ankle
foot orthotics (AFO’s) is preferable for use when the plantar
ﬂexion weakness and inability to control the ankle is present.
They are small, light and provide good functional beneﬁt.45
A solid AFO is only appropriate when severe spasticity must
be controlled, and this is the case in RFS survivors as deﬁcits
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ost commonly affect the peripheral nervous system.45 If
nee extension weakness and difﬁculty with dorsiﬂexion are
resent, the knee immobilizer may be used.46
.4.  Medications
edications are needed to control pain and muscle spasms
n RFS. In patients with neuropathic pain, treatment with
erve stabilizer is indicated in the ﬁrst line. Opioids are often
dded to either or both pregabalin and duloxetine when
eeded. Newer agents, particularly pregabalin, are gener-
lly preferred rather than older agents such as the tricyclic
ntidepressants because they have efﬁcacy and little potential
or drug–drug interactions.47 Nonsteroidal anti-inﬂammatory
rugs are generally recommended when pain from inﬂamma-
ion of adhesive capsulitis, degenerative changes is diagnosed.
pioids relieve pain but are not effective for muscle spasm
nd other neuropathic symptoms. They should generally be
eserved for second-line use or added to nerve-stabilizing
gents when treating pain in RFS. Muscle relaxants including
aclofen, and bezodiazepines may help relieve the pain associ-
ted with muscle spasms.48 Trigger-points injection is simply
n injection of local anesthetic into the area of a painful mus-
le spasm. It may be of beneﬁt to patients with muscle pain
n the trapezius, rhomboids, cervical paraspinal muscles.49,50
otulinum toxin injection has a potential beneﬁt in several
peciﬁc complications of RFS, including cervical dystonia, tris-
us, painful muscle spasms, spasticity, and focal neuropathic
ain disorders.26,51,52
.5.  Prevention  of  RFS
he prevention of radiation-induced ﬁbrosis has focused on
he improvements in RT technique, which have resulted
n higher doses to the tumor target and decreased doses
o normal tissue, thus potentially preventing the develop-
ent of radiation-induced ﬁbrosis. Furthermore, established
adiation-induced ﬁbrosis may be treatable with novel
herapeutic approaches, particularly the combination of pen-
oxifylline and vitamin E.53 With the progress of clinical
esearch, Chuai et al.31 believe that hydrogen-rich solution will
ive us more  hope for the prevention of radiation pneumonitis.
.  Conclusion
FS is a serious and lifelong disorder. Various complications
f RFS are usually treatable although they require vigilance on
he part of the physician. When the treatment is conducted
long with rehabilitation, and when identiﬁed early, these dis-
rders are often decremented.
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